By integrating bioinformatic, experimental, and clinical evidence, this study expands the current understanding of ADGRG6 biology in pancreatic cancer and provides a conceptual framework for exploring ADGRG6 as a therapeutic target in future precision oncology and immunomodulation studies. Here, ADGRG6 is linked to pancreatic neoplasm.